Mumbai: The United States Food and Drug Administration (US FDA) has placed Sun Pharmaceuticals' Halol unit under 'import alert'.

This implies that all future shipments of products manufactured at this facility are subject to refusal of admission to the US market until the facility becomes compliant with cGMP standards.

The US FDA inspected Sun Pharma's Halol unit from April 26 to May 9, 2022. The US FDA has excluded 14 products from this import alert subject to certain conditions.

The company said that supplies to the US market from the Halol facility accounted for roughly 3 per cent of its consolidated revenue for the year ended March 31, 2022, including the 14 excluded products mentioned above.

"The Company continues to cooperate with the USFDA and will undertake all necessary steps to resolve these issues and to ensure that the regulator is completely satisfied with the Company’s remedial action," the company said in a statement to the exchanges.

Sun Pharma's stock dipped following the disclosure. As of 10:20 am, the scrip was trading with a loss of 2.37 per cent while the broader index was trading up 0.24 per cent.

Govt soon to set up Export Promotion Council for Medical Devices

CDSCO Panel gives nod for FDC Tamsulosin + Solifenacin

IPC alert: About Norfloxacin induced skin hyperpigmentation

NPPA releases 4th list of draft ceiling prices for 15 formulations

J&J baby powder sample fails quality test: FDA latest lab report

NPPA releases 3rd list with draft ceiling prices for 43 formulations

Drug recall: Sodium Bicarbonate Injection recalled due to this reason

USFDA-Gujarat FDCA to meet to discuss GMP compliance, capacity building

CDSCO panel gives nod for Esomeprazole Dual Release Gastro resistant tablets

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/12/08/usfda-lists-sun-pharmas-halol-unit-under-import-alert/